Etanercept Use During Pregnancy

Safety Profile and Recommendations

• The American College of Rheumatology conditionally recommends etanercept for use prior to and during pregnancy, with consideration for discontinuation in the third trimester if disease is well controlled 1
• Etanercept contains an Fc IgG1 construct that does not cross the placenta in significant concentrations until the second trimester, making it relatively safe during early pregnancy 1
• Continuing etanercept is conditionally recommended during the first and second trimesters of pregnancy, as studies show minimal placental transfer during early pregnancy 1, 2
• If disease is well-controlled, consider discontinuing etanercept in the third trimester, but if active disease persists, continuing etanercept through delivery can be considered 1
• The American College of Rheumatology suggests that the risk of untreated or poorly controlled rheumatic disease during pregnancy may outweigh potential risks of etanercept exposure, and disease activity is correlated with adverse pregnancy outcomes 1